Ovuclon100 mg

Ovuclon is indicated for the treatment of ovulatory dysfunction in women who wish to become pregnant and who have been found to have adequate estrogen levels.

Established Use

• Ovulation induction in anovulatory or oligo-ovulatory women desiring pregnancy, including women with polycystic ovary syndrome (PCOS), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, and post-oral-contraceptive amenorrhea, once other causes of infertility (e.g. tubal disease, male factor infertility, thyroid or adrenal dysfunction, hyperprolactinemia) have been excluded or addressed.

Before starting Ovuclon, a physician should confirm that the patient is not already pregnant, has normal liver function, and does not have an ovarian cyst other than one caused by PCOS.

Off-Label / Adjunct Use

Ovuclon is also used off-label in some fertility protocols (for example, in combination with gonadotropins or timed intercourse/intrauterine insemination) under specialist supervision; such use should be individualized by a fertility specialist and is not an FDA-approved indication.

Each tablet contains Clomiphene Citrate USP as the active ingredient, commonly available in 50 mg strength (also available as 100 mg in some markets), along with pharmaceutically approved excipients.

Ovuclon is an orally active, non-steroidal ovulatory stimulant belonging to the class of selective estrogen receptor modulators (SERMs). It is chemically related to triphenylethylene compounds and is structurally similar to other anti-estrogenic agents.

Ovuclon is used to induce ovulation in women who do not ovulate regularly, so that they have the opportunity to conceive. It is taken as a short course of tablets early in the menstrual cycle under the guidance of a physician, with monitoring of ovarian response.

Ovuclon belongs to the therapeutic class of ovulation-inducing agents / selective estrogen receptor modulators (SERMs), also referred to as anti-estrogens used for fertility treatment.

Clomiphene Citrate is a selective estrogen receptor modulator (SERM) with mixed estrogen agonist/antagonist properties. Its predominant action is as an estrogen antagonist at the hypothalamus, where it competitively binds to and blocks estrogen receptors, interfering with the normal negative feedback of circulating estradiol.

The hypothalamus interprets this as a low-estrogen state, leading to increased secretion of gonadotropin-releasing hormone (GnRH), which in turn increases pituitary release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). This increase in gonadotropins stimulates ovarian follicular development and, ultimately, ovulation.

Ovulation typically occurs 5–10 days after the last dose of Clomiphene Citrate (usually around day 14–18 of the treatment cycle) in patients who respond to therapy. Clomiphene Citrate does not directly stimulate the ovary; its effect is mediated through the hypothalamic-pituitary-ovarian axis.

Ovuclon tablets are taken by mouth, with or without food, at approximately the same time each day for the prescribed 5-day course. Tablets should be swallowed whole with a glass of water. Do not alter the dose or duration without consulting a physician.

Ovuclon has minimal well-established clinically significant drug-drug interactions, given its specific hormonal mechanism of action limited largely to the hypothalamic-pituitary-ovarian axis.

No formal drug interaction studies with clinically significant findings are established in the labeling. Patients should nonetheless inform their physician of all medications, supplements, and hormonal therapies they are using before starting Ovuclon, particularly other fertility medications (e.g. gonadotropins) which may be used together only under specialist supervision.

Most side effects of Ovuclon are mild and related to its hormonal mechanism of action.

Common

• Ovarian enlargement (a normal, expected pharmacologic response in many patients)
• Hot flashes / vasomotor flushing
• Abdominal or pelvic discomfort, bloating
• Nausea and vomiting
• Breast tenderness or discomfort
• Headache
• Abnormal uterine bleeding or spotting
• Mood changes/irritability

Less Common but Important

• Visual disturbances — blurred vision, spots, or flashes of light (scintillating scotomata); see Precautions and Warnings.
• Ovarian hyperstimulation syndrome (OHSS) — see Precautions and Warnings.
• Multiple pregnancy — an increased likelihood of twins or higher-order multiple pregnancy; an important counseling point rather than a direct side effect.

Rare

• Hair thinning, weight changes, vaginal dryness
• Hypertriglyceridemia, and rarely pancreatitis, especially with higher doses or prolonged use

Pregnancy: Ovuclon is contraindicated once pregnancy is confirmed or suspected. It is specifically used to help achieve ovulation and pregnancy, and must be discontinued as soon as pregnancy is confirmed. Pregnancy should be excluded by a physician before each treatment course. Available human data have not shown a clearly increased risk of congenital anomalies above the background population risk when Ovuclon is used as indicated for ovulation induction, but animal studies have shown adverse fetal effects at high doses, so Ovuclon should only be used under close medical supervision and exactly as prescribed.

Lactation: It is not known whether Ovuclon is excreted in human breast milk. Ovuclon may reduce or inhibit lactation in some women. Use during breastfeeding should only occur if clearly needed and after consulting a physician, since Ovuclon is generally used prior to conception rather than during an established pregnancy or lactation period for its approved indication.

Ovarian Hyperstimulation Syndrome (OHSS)

Ovuclon can cause ovarian enlargement and, in some patients, ovarian hyperstimulation syndrome (OHSS), a potentially serious condition that can progress rapidly (within 24 hours to several days) and may include gross ovarian enlargement, abdominal pain, gastrointestinal symptoms, ascites, pleural effusion, difficulty breathing, and reduced urine output. Rare but serious complications include venous thromboembolism, ovarian torsion or hemorrhage, and, very rarely, death. The lowest effective dose should be used, and patients should be examined for ovarian enlargement before each treatment course and instructed to report abdominal or pelvic pain, distention, or weight gain promptly.

Visual Disturbances

Blurred vision or other visual symptoms such as spots or flashes of light (scintillating scotomata) may occasionally occur during Ovuclon therapy, more often with higher doses or longer duration of use. These effects are usually reversible after stopping treatment but may occasionally be prolonged or irreversible. Patients should discontinue Ovuclon immediately and seek prompt ophthalmological evaluation if any visual symptoms occur, and should avoid driving or operating machinery if vision is affected.

Multiple Pregnancy

Ovulation induction with Ovuclon significantly increases the likelihood of multiple pregnancy (twins or higher-order multiples) compared with natural conception. Patients should be counseled about this risk, including the associated obstetric and neonatal risks, before starting treatment.

Duration of Treatment

Ovuclon should generally not be used for more than about 6 ovulatory cycles; prolonged or repeated use beyond this without reassessment is not recommended and has been associated in some studies with a possible increased risk of ovarian tumors, though a causal relationship has not been firmly established.

Other Precautions

• Use with caution in patients with a history of liver disease (liver function should be normal before starting).
• Monitor triglycerides in patients with pre-existing hypertriglyceridemia, as Ovuclon may raise triglyceride levels.
• Enlarged ovaries associated with Ovuclon usually return to normal size within a few weeks after stopping treatment; patients should avoid activities that could rupture an enlarged ovary (e.g. strenuous exercise, intercourse) until it resolves.

Overdose of Ovuclon may cause nausea, vomiting, hot flashes, visual blurring or spots before the eyes, and ovarian enlargement with abdominal or pelvic pain.

There is no specific antidote. If an overdose of Ovuclon is suspected, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; a physician may advise gastric decontamination measures if the ingestion is recent and appropriate. Do not attempt to manage a suspected overdose at home without medical guidance.

Store at room temperature (below 30°C), protected from light, heat, and excessive humidity. Keep out of reach of children.

Renal/Hepatic Impairment

Ovuclon is contraindicated in patients with liver disease or significant hepatic dysfunction. There is no well-established dose adjustment for renal impairment; use with caution and physician supervision.

Elderly

Ovuclon is used exclusively in women of reproductive age for ovulation induction; it has no indicated use in elderly patients.

Pediatric Population

Ovuclon is not indicated for use in children; safety and efficacy in the pediatric population have not been established, as this is an infertility treatment intended for adult women.

PCOS and Ovarian Sensitivity

Women with polycystic ovary syndrome may be more sensitive to Ovuclon and are at higher risk of ovarian hyperstimulation; such patients may require lower or more carefully titrated doses under specialist supervision.

A standard course of Ovuclon is 5 days per cycle. Treatment is generally not continued beyond approximately 6 ovulatory cycles; if pregnancy has not occurred after 3 ovulatory cycles at an adequate dose, or if ovulation does not occur after 3 cycles, the treating physician should reassess the treatment plan.

Selective estrogen receptor modulator (SERM); ovulation-inducing agent / anti-estrogen (fertility agent).

Clomiphene Citrate acts as a competitive antagonist at hypothalamic estrogen receptors, blocking normal estrogen negative feedback. This tricks the hypothalamus into perceiving a low-estrogen state, increasing GnRH pulsatility and subsequent pituitary secretion of FSH and LH, which stimulates ovarian follicular growth and triggers ovulation.

X

Ovuclon is not indicated for use in children or adolescents who have not reached reproductive maturity. It is used only in adult women of reproductive age for ovulation induction; safety and efficacy in pediatric patients have not been established.